机构：[1]Hebei Univ,Dept Radiat Oncol,Affiliated Hosp,Baoding,Peoples R China河北大学附属医院[2]Hebei Univ,Dept Med Oncol,Affiliated Hosp,Baoding 071000,Peoples R China医疗肿瘤内科河北大学附属医院重点学科肿瘤内科
Aim: We performed a meta-analysis to evaluate the incidence and risk factors of severe rash associated with the use of EGFR tyrosine kinase inhibitors (TKIs). Methods: PubMed, EMBASE and oncology conference proceedings were searched for articles published till March 2016. Results: A total of 18,309 patients from 37 randomized controlled trials were available for the meta-analysis. The overall incidence for severe rash was 6.6% (95% CI: 5.2-8.3%) among patients receiving EGFR-TKIs. The use of EGFR-TKIs significantly increased the risk of developing severe rash (risk ratio: 7.70; 95% CI: 5.79-10.23) in cancer patients. On subgroup analysis, the increased risk of severe rash was driven predominantly by drug type (p = 0.002). Conclusion: EGFR-TKIs significantly increase the risk of developing severe rash in cancer patients.
第一作者机构：[1]Hebei Univ,Dept Radiat Oncol,Affiliated Hosp,Baoding,Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Xi,Ran Yu-Ge,Wang Kun-Jie.Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis[J].FUTURE ONCOLOGY.2016,12(23):2741-2753.doi:10.2217/fon-2016-0180.
APA：
Zhang, Xi,Ran, Yu-Ge&Wang, Kun-Jie.(2016).Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.FUTURE ONCOLOGY,12,(23)
MLA：
Zhang, Xi,et al."Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis".FUTURE ONCOLOGY 12..23(2016):2741-2753
